Inmune-mediated inflammatory rheumatic diseases in transgender people: A scoping review.
Semin Arthritis Rheum
; 52: 151920, 2022 02.
Article
en En
| MEDLINE
| ID: mdl-34872742
ABSTRACT
BACKGROUND:
In immune-mediated inflammatory rheumatic diseases (IMIRD), there are differences between cis-men and cis-women in epidemiology, clinical feature, therapeutic approach, treatment response, and prognosis. In transgender individuals, information concerning IMIRD is not substantial. The assessment of information concerning rheumatic diseases in transgenders is crucial because transgenders may undergo treatments with potential impacts on IMIRD. We aim to collect and discuss current knowledge on IMIRD in transgender individuals, determine the coverage of the literature, identify the knowledge gaps, and highlight opportunities for future research.METHODS:
We did a scoping review of publications collected through a systematic search of transgender patients with any IMIRD. Data sources were Medline, Embase, and Web of Knowledge. Synthesis of results and qualitative review of data information was collected in tables. A semi-quantification of the quality of the articles reporting clinical studies was performed.RESULTS:
There were 11 transwoman, and 3 transmen cases of systemic lupus erythematosus (5 cases), skin lupus erythematosus (2), systemic sclerosis (4), anti-synthetase syndrome (1), rheumatoid arthritis (1) and ankylosing spondylitis (1). Eleven were de novo cases and three had prior history of IMIRD and developed a comorbidity after starting hormone replacement therapy. The clinical expression of the disease was variable. Two transwomen and one transman developed thrombotic events. The lupus skin lesions in one transman improved following testosterone treatment. No clinical studies were identified. Quality of publications was disparate.CONCLUSION:
Although the number of cases is small, most cases of IMIRD occur in transwomen. The absence of solid data warrants caution in establishing recommendations regarding hormone replacement therapy in transgenders with IMIRD. There is an essential need for the consideration of cisgender and transgender particularities in future research on IMIRD.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Fiebre Reumática
/
Enfermedades Reumáticas
/
Personas Transgénero
/
Lupus Eritematoso Sistémico
Tipo de estudio:
Guideline
/
Prognostic_studies
/
Qualitative_research
/
Systematic_reviews
Límite:
Female
/
Humans
/
Male
Idioma:
En
Año:
2022
Tipo del documento:
Article